3.74Open3.74Pre Close0 Volume0 Open Interest10.00Strike Price0.00Turnover167.90%IV-6.66%PremiumApr 17, 2025Expiry Date4.72Intrinsic Value100Multiplier11DDays to Expiry0.00Extrinsic Value100Contract SizeAmericanOptions Type0.9256Delta0.0319Gamma3.00Leverage Ratio-0.0273Theta0.0028Rho2.78Eff Leverage0.0037Vega
Takeda Pharmaceutical Stock Discussion
Can This New Drug Cut Blood Draws by 72% for Polycythemia Vera Patients?
New TAKHZYRO Pen Makes HAE Treatment More Accessible - What This Means for Patients
AC Immune SA - AC Immune to Receive Upfront Payment of $100 Mln Upon Closing
The NT1 trial TAK-861-2001 evaluating TAK-861 in 112 patients demonstrated statistically significant and clinically meaningful improvement in objective and subjective measures of wakefulness compared to placebo at week 8 including on the primary endpoint Maintenance of Wakefulness Test (MWT) (p < 0.001).
Plans To Initiate Global Phase 3 Trials Of TAK-861 In Narcolep...
Let's take a look at a few of the different types of artificial intelligence and healthcare industry benefits that can be derived from their use.
The Competition to Discover the First Drug with AI
Insilico Medicine, ...
No comment yet